UniProtKB/Swiss-Prot P28223: Variant p.His452Tyr

5-hydroxytryptamine receptor 2A
Gene: HTR2A
Feedback?

Variant information Variant position:

452 The position of the amino-acid change on the UniProtKB canonical protein sequence.
Type of variant:

LB/B The variants are classified into three categories: LP/P, LB/B and US.

LP/P: likely pathogenic or pathogenic.
LB/B: likely benign or benign.
US: uncertain significance

Residue change:

From Histidine (H) to Tyrosine (Y) at position 452 (H452Y, p.His452Tyr). Indicates the amino acid change of the variant. The one-letter and three-letter codes for amino acids used in UniProtKB/Swiss-Prot are those adopted by the commission on Biochemical Nomenclature of the IUPAC-IUB.
Physico-chemical properties:

Change from medium size and polar (H) to large size and aromatic (Y) The physico-chemical property of the reference and variant residues and the change implicated.
BLOSUM score:

2 The score within a Blosum matrix for the corresponding wild-type to variant amino acid change. The log-odds score measures the logarithm for the ratio of the likelihood of two amino acids appearing by chance. The Blosum62 substitution matrix is used. This substitution matrix contains scores for all possible exchanges of one amino acid with another:

Lowest score: -4 (low probability of substitution).
Highest score: 11 (high probability of substitution).

More information can be found on the following page
Other resources:

Links to websites of interest for the variant.

Variant rs6314 [ dbSNP | Ensembl ]

Sequence information Variant position:

452 The position of the amino-acid change on the UniProtKB canonical protein sequence.
Protein sequence length:

471 The length of the canonical sequence.
Location on the sequence:

SKQDAKTTDNDCSMVALGKQ H SEEASKDNSDGVNEKVSCV The residue change on the sequence. Unless the variant is located at the beginning or at the end of the protein sequence, both residues upstream (20) and downstream (20) of the variant will be shown.
Residue conservation:

The multiple alignment of the region surrounding the variant against various orthologous sequences.

Human                         SKQDAKTTDNDCSMVALGKQHSEEASKDNSDGVNEKVSCV

                              SKKDAKSTDNDYSMVALGKQHSEDAPTDNINTVNEKVSCV

Rhesus macaque                SKQDAKTTDNDCSMVALGKQHSEDASKDNSDGVNEKVSCV

Mouse                         SQEDAEPTANDCSMVTLGNQHSEEMCTDNIETVNEKVSCV

Rat                           SQEDAEQTVDDCSMVTLGKQQSEENCTDNIETVNEKVSCV

Pig                           SKQDDKATENDCTMVALGKQHSEDAPADNSNTVNEKVSCV

Bovine                        SKKDDKTTDNDCTMVALGKEHPEDAPADSSNTVNEKVSCV

Drosophila                    ----------------------------------------

Sequence annotation in neighborhood:

The regions or sites of interest surrounding the variant. In general the features listed are posttranslational modifications, binding sites, enzyme active sites, local secondary structure or other characteristics reported in the cited references. The "Sequence annotation in neighborhood" lines have a fixed format:

Type: the type of sequence feature.
Positions: endpoints of the sequence feature.
Description: contains additional information about the feature.

Type	Positions	Description
Chain	1 – 471	5-hydroxytryptamine receptor 2A
Topological domain	385 – 471	Cytoplasmic
Region	450 – 471	Disordered
Mutagenesis	463 – 463	G -> V. Loss of interaction with PATJ.
Mutagenesis	465 – 465	N -> S. No effect on interaction with PATJ. Acquires the binding properties of HTR2C; when associated with S-470.
Mutagenesis	470 – 470	C -> S. No effect on interaction with PATJ. Acquires the binding properties of HTR2C; when associated with S-465.
Mutagenesis	471 – 471	V -> A. Loss of interaction with PATJ, CASK, APBA1, DLG1 and DLG4.

Literature citations
Systematic screening for mutations in the human serotonin-2A (5-HT2A) receptor gene: identification of two naturally occurring receptor variants and association analysis in schizophrenia.
Erdmann J.; Shimron-Abarbanell D.; Rietschel M.; Albus M.; Maier W.; Koerner J.; Bondy B.; Chen K.; Shih J.C.; Knapp M.; Propping P.; Noethen M.M.;
Hum. Genet. 97:614-619(1996)
Cited for: VARIANTS ASN-25 AND TYR-452; Unified approach to the analysis of genetic variation in serotonergic pathways.
Marshall S.E.; Bird T.G.; Hart K.; Welsh K.I.;
Am. J. Med. Genet. 88:621-627(1999)
Cited for: VARIANTS ASN-25 AND TYR-452; Characterization of single-nucleotide polymorphisms in coding regions of human genes.
Cargill M.; Altshuler D.; Ireland J.; Sklar P.; Ardlie K.; Patil N.; Shaw N.; Lane C.R.; Lim E.P.; Kalyanaraman N.; Nemesh J.; Ziaugra L.; Friedland L.; Rolfe A.; Warrington J.; Lipshutz R.; Daley G.Q.; Lander E.S.;
Nat. Genet. 22:231-238(1999)
Cited for: VARIANTS VAL-197; VAL-447 AND TYR-452;

Disclaimer: Any medical or genetic information present in this entry is provided for research, educational and informational purposes only. They are not in any way intended to be used as a substitute for professional medical advice, diagnostic, treatment or care.